<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717102</url>
  </required_header>
  <id_info>
    <org_study_id>Desflurane01</org_study_id>
    <nct_id>NCT04717102</nct_id>
  </id_info>
  <brief_title>Evaluating the Use of 0.5 and 0.75 MAC Desflurane in Patients Undergoing Spinal Surgery</brief_title>
  <official_title>Evaluating the Use of Desflurane in Patients Undergoing Spinal Surgery: A Randomized Controlled Trial Using 0.5 and 0.75 MAC Desflurane</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Somatosensory- (SSEPs) and motor-evoked potentials (MEPs) are commonly used as an&#xD;
      intraoperative neurophysiologic monitoring tool to detect aberrations to the spinal cord&#xD;
      integrity during spinal surgery. Inhalational anaesthetic agents have a significant influence&#xD;
      on evoked potentials by suppressing the amplitude and prolonging the latency. Evidences&#xD;
      suggest that total intravenous anaesthesia (TIVA) is superior to inhalation anaesthesia for&#xD;
      neuromonitoring in spinal surgery, and support the use of up to 0.5 minimum alveolar&#xD;
      concentration (MAC) of inhalational anaesthetic agents in these procedures.&#xD;
&#xD;
      Methods: Patients undergoing spinal surgeries will be prospectively recruited and be induced&#xD;
      with TIVA at baseline of the evoked potentials. They will be randomized to receive balance&#xD;
      anaesthesia with A) Desflurane MAC 0.5+remifentanil, or B) Desflurane MAC 0.75+remifentanil&#xD;
      until the end of surgery. Influence of 1.0 MAC desflurane on the evoked potentials after the&#xD;
      completion of surgery will also be studied.&#xD;
&#xD;
      Desired Results: Endpoints include the changes to the amplitude and latency of SSEPs and MEPs&#xD;
      with 0.5 and 0.75 MAC desflurane. The findings will indicate the safety of desflurane at the&#xD;
      studied concentrations for spinal surgeries, and substantial savings with the use of&#xD;
      desflurane instead of TIVA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recording of Evoked Potentials characteristics:&#xD;
&#xD;
      The following characteristics of the evoked potential signals will be recorded:&#xD;
&#xD;
        -  Amplitude: Size of the response, measured in microvolts (Î¼V)&#xD;
&#xD;
        -  Latency: Speed of the response, measured in milliseconds (ms)&#xD;
&#xD;
        -  Morphology: Appearance of the response - Simple/Complex wave shape Baseline evoked&#xD;
           potentials will be recorded at various points of surgery.&#xD;
&#xD;
      Anaesthesia variables:&#xD;
&#xD;
      At the time of recording of evoked potentials:&#xD;
&#xD;
      - Intraoperative temperature, blood pressure, ETCO2, anaesthesia depth - bispectral index&#xD;
      monitoring (BIS), remifentanil TCI, MAC of desflurane, Train of Four, volume of propofol and&#xD;
      remifentanil until randomization, total volume of desflurane and remifentanil used,&#xD;
      anaesthetic medications used, FiO2, SpO2&#xD;
&#xD;
      Patient characteristics:&#xD;
&#xD;
      - Age, gender, race, weight, BMI, medications used, haematocrit, preop blood glucose (for&#xD;
      Diabetics)&#xD;
&#xD;
      Safety considerations:&#xD;
&#xD;
      'Recommended standards for intraoperative monitoring of somatosensory evoked potentials',&#xD;
      Guideline 11B of the American Clinical Neurophysiology Society (2009) and 'Intraoperative&#xD;
      motor evoked potential monitoring - A position statement by the American Society of&#xD;
      Neurophysiological Monitoring' will form the basis of the safety aspects of the study.&#xD;
&#xD;
      Conduct of Anaesthesia:&#xD;
&#xD;
        -  The induction of anaesthesia will be achieved using targeted propofol and remifentanil&#xD;
           infusions (TIVA). Muscle relaxants atracurium, rocuronium or suxamethonium will be used&#xD;
           to facilitate intubation.&#xD;
&#xD;
        -  Anaesthesia will be maintained on TIVA until the patient has recovered from muscle&#xD;
           relaxant. Baseline characteristics (BC1) of the evoked potentials in TIVA will be&#xD;
           obtained at this stage.&#xD;
&#xD;
        -  Once the BC1 has been obtained, the patients will be randomized to two groups:&#xD;
&#xD;
      Group A- Anaesthesia maintained with 0.5 MAC desflurane/remifentanil infusion Group B-&#xD;
      Anaesthesia maintained with 0.75MAC desflurane/remifentanil infusion&#xD;
&#xD;
        -  Baseline characteristics 2 (BC2) will be obtained and the decision to proceed with 0.5&#xD;
           or 0.75 MAC desflurane made.&#xD;
&#xD;
        -  On completion of the neuromonitoring phase of surgery, as defined by completion of&#xD;
           instrumentation and start of closure, all patients in Group A and B will be maintained&#xD;
           with 1.0 MAC desflurane with remifentanil infusion. Baseline characteristics 3 (BC3)&#xD;
           will be recorded at this stage.&#xD;
&#xD;
        -  The remifentanil infusion will be titrated at various stages of surgery to maintain a&#xD;
           stable BIS and will also be based on haemodynamic variables.&#xD;
&#xD;
      All patients will get additional analgesics and antiemetics as deemed necessary.&#xD;
      Post-operative recovery will follow the standard industry norms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of 0.5 MAC desflurane on evoked potentials - Amplitude (microvolts)</measure>
    <time_frame>During surgery</time_frame>
    <description>Amplitude of somatosensory- and motor- evoked potentials with use of 0.5 MAC desflurane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 0.5 MAC desflurane on evoked potentials - Latency (milliseconds)</measure>
    <time_frame>During surgery</time_frame>
    <description>Latency of somatosensory- and motor- evoked potentials with use of 0.5 MAC desflurane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 0.5 MAC desflurane on evoked potentials - Morphology (appearance of the response)</measure>
    <time_frame>During surgery</time_frame>
    <description>Morphology of somatosensory- and motor- evoked potentials with use of 0.5 MAC desflurane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 0.75 MAC desflurane on evoked potentials - Amplitude (microvolts)</measure>
    <time_frame>During surgery</time_frame>
    <description>Amplitude of somatosensory- and motor- evoked potentials with use of 0.75 MAC desflurane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 0.75 MAC desflurane on evoked potentials - Latency (milliseconds)</measure>
    <time_frame>During surgery</time_frame>
    <description>Latency of somatosensory- and motor- evoked potentials with use of 0.75 MAC desflurane</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of 0.75 MAC desflurane on evoked potentials - Morphology (appearance of the response)</measure>
    <time_frame>During surgery</time_frame>
    <description>Morphology of somatosensory- and motor- evoked potentials with use of 0.75 MAC desflurane</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of 1.0 MAC desflurane on evoked potentials - Amplitude (microvolts)</measure>
    <time_frame>intraoperative</time_frame>
    <description>Amplitude of somatosensory- and motor- evoked potentials with use of 1.0 MAC desflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1.0 MAC desflurane on evoked potentials - Latency (milliseconds)</measure>
    <time_frame>intraoperative</time_frame>
    <description>Latency of somatosensory- and motor- evoked potentials with use of 1.0 MAC desflurane</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of 1.0 MAC desflurane on evoked potentials - Morphology (appearance of the response)</measure>
    <time_frame>intraoperative</time_frame>
    <description>Morphology of somatosensory- and motor- evoked potentials with use of 1.0 MAC desflurane</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>0.75 MAC desflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The effects of 0.75 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 MAC desflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The effects of 0.5 MAC desflurane on the amplitude and latency of evoked potentials in spinal surgeries will be examined.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 MAC desflurane</intervention_name>
    <description>Following induction of anesthesia by propofol, the patients will be maintained on 0.5 MAC desflurane with remifentanil infusion during spinal surgery.</description>
    <arm_group_label>0.5 MAC desflurane</arm_group_label>
    <other_name>0.5 MAC desflurane (Suprane)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.75 MAC desflurane</intervention_name>
    <description>Following induction of anesthesia by propofol, the patients will be maintained on 0.75 MAC desflurane with remifentanil infusion during spinal surgery.</description>
    <arm_group_label>0.75 MAC desflurane</arm_group_label>
    <other_name>0.75 MAC desflurane (Suprane)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0 MAC desflurane</intervention_name>
    <description>On completion of the neuromonitoring phase of surgery, the patients will be maintained on 1.0 MAC desflurane with remifentanil infusion.</description>
    <arm_group_label>0.5 MAC desflurane</arm_group_label>
    <arm_group_label>0.75 MAC desflurane</arm_group_label>
    <other_name>1.0 MAC desflurane (Suprane)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged â¥ 21 years old, scheduled for spinal surgery.&#xD;
&#xD;
          -  Patients who require SSEP/MEP and with no neurological deficits.&#xD;
&#xD;
          -  Patients of American Society of Anesthesiologist I-III physical status.&#xD;
&#xD;
          -  Consenting patients.&#xD;
&#xD;
          -  Elective procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with sensory or motor deficits preoperatively.&#xD;
&#xD;
          -  Patients with significant cardiovascular and/or respiratory disease.&#xD;
&#xD;
          -  Emergency procedures.&#xD;
&#xD;
          -  Cord injury secondary to trauma.&#xD;
&#xD;
          -  Non-consenting patients.&#xD;
&#xD;
          -  Category A patients (Prisoners).&#xD;
&#xD;
          -  Patients with previous stroke.&#xD;
&#xD;
          -  Patients with Hep C, HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai May Leong, MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seok Hwee Koo, PhD</last_name>
    <phone>+6568504929</phone>
    <email>seok_hwee_koo@cgh.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lay Hwa Yew</last_name>
    </contact>
    <investigator>
      <last_name>Rajkumar Chandran</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prit Anand Singh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shree Kumar Dinesh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seok Hwee Koo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wee Lim Loo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terry Teo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Hasan MS, Tan JK, Chan CYW, Kwan MK, Karim FSA, Goh KJ. Comparison between effect of desflurane/remifentanil and propofol/remifentanil anesthesia on somatosensory evoked potential monitoring during scoliosis surgery-A randomized controlled trial. J Orthop Surg (Hong Kong). 2018 May-Aug;26(3):2309499018789529. doi: 10.1177/2309499018789529.</citation>
    <PMID>30058437</PMID>
  </reference>
  <reference>
    <citation>Sloan TB, Toleikis JR, Toleikis SC, Koht A. Intraoperative neurophysiological monitoring during spine surgery with total intravenous anesthesia or balanced anesthesia with 3% desflurane. J Clin Monit Comput. 2015 Feb;29(1):77-85. doi: 10.1007/s10877-014-9571-9. Epub 2014 Mar 19.</citation>
    <PMID>24643708</PMID>
  </reference>
  <reference>
    <citation>Macdonald DB, Skinner S, Shils J, Yingling C; American Society of Neurophysiological Monitoring. Intraoperative motor evoked potential monitoring - a position statement by the American Society of Neurophysiological Monitoring. Clin Neurophysiol. 2013 Dec;124(12):2291-316. doi: 10.1016/j.clinph.2013.07.025. Epub 2013 Sep 18. Review.</citation>
    <PMID>24055297</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changi General Hospital</investigator_affiliation>
    <investigator_full_name>Leong Wai May</investigator_full_name>
    <investigator_title>Senior Consultant</investigator_title>
  </responsible_party>
  <keyword>evoked potentials</keyword>
  <keyword>spinal surgery</keyword>
  <keyword>desflurane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

